Dr. Chatterjee has over 30 years of broad strategic and operational experience in pharmaceutical research and development, and in business development and licensing.

She currently serves on the board of directors of Editas Medicines and Werewolf Therapeutics.

Dr. Chatterjee served as the Senior Vice President of Global Business Development and Alliance Management at Legend Biotech Corporation until November 2022. She previously served in roles of increasing seniority and responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., as Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group. Dr. Chatterjee oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies. She also was responsible for Merck’s BD&L governance, oversight, and control as well as out-licensing efforts. 

Meeta started her career at Schering-Plough Research Institute (SPRI) in the cardiovascular research department and subsequently as head of R&D Licensing at SPRI.  She led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA® and ZONTIVITY®.

Dr. Chatterjee received her undergraduate education at St. Xavier’s University in Ahmedabad, India, and Rutgers University (B.A., Hons Physics). She received her Doctor of Philosophy in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine.